Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Beamion PANTUMOR 1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2 mutated or overexpressed/amplified solid tumours'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National Cancer Centre
Trial Status: NA
Principal Investigator(s):
Dr Tira Tan Jing Ying
Published by HT Digital Content Services with permission from Health Daily Digest....